Combined glyburide and insulin therapy in type II diabetes

A. Reich, C. Abraira, A. M. Lawrence

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Present treatment of type II diabetes mellitus often fails to normalize post-prandial glucoses. A placebo-controlled, double-blinded design tested the effects of combined glyburide-insulin therapy over 4 months in 20 patients after achieving good control of fasting glucose with diet and intermediate insulin alone. Insulin requirements significantly decreased in both groups during the initial hospitalization when drug or placebo was added, presumably because of enformed dietary compliance. Thereafter, post-prandial glucoses worsened in the placebo group, as did hemoglobin A1(c); neither of these parameters changed on the glyburide group by week 16, except for modest reduction of the 2 h post-lunch glucose. Thus, while combined therapy provides little advantage beyond what can be accomplished with effective doses of intermediate insulin alone, it did reduce the need for this exogenous insulin.

Original languageEnglish (US)
Pages (from-to)99-104
Number of pages6
JournalDiabetes Research
Issue number2
StatePublished - Dec 1 1987

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine


Dive into the research topics of 'Combined glyburide and insulin therapy in type II diabetes'. Together they form a unique fingerprint.

Cite this